Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
dutasteride
ARI40006
NCT00056407
Neoplasms, Prostate
Phase 3
 
A follow-up study ARI103094 was conducted.
September 2013

Powered by ideaPoint, Inc.